GSK buys full rights to make COVID, influenza vaccines from CureVac
![22451886](/images/1056x594/jpg/files/rss/22451886_1.jpg)
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
More info